In September 2022, the Recombinant SARS-COV-2 Fusion Protein Vaccine LIKANG V-01 developed by Livzon Mabpharm Inc. in collaboration with the Institute of Biophysics, Chinese Academy of Sciences, was proposed by the National Health Commission and approved by the National Medical Products Administration upon demonstration to be included for the emergency use as sequential booster immunization.

Likang V-01, with its "upgraded" recombinant protein immunogenicity and unique molecular design, is expected to overcome the main limitations and uncertainties of the first-generation SARS-CoV-2 vaccine and become a new generation of high-quality vaccine. 

According to the clinical study data, on the basis of two-dose inactivated vaccine primary immunization, the absolute efficacy of Likang V-01 booster was 61.35%. It reached 61.19% for high-risk group (aged 60 and above and population with underlying diseases). Likang V-01 also showed excellent safety profile compared to mRNA vaccine and Adenovirus vaccine. It can alleviate the urgent demand for SARS-CoV-2 vaccines globally, and provide a better solution for global immunization.